To prepare individual 0.3 mL doses from the diluted multiple dose vial

Using either thawing method, vials must reach room temperature before dilution and must be diluted within 2 hours. Do not refreeze thawed vials.

4.

The declaration is terminated or authorization revoked sooner.

Refer to the FDA-authorized Fact Sheet for Vaccination Providers including Full Emergency Use Authorization Prescribing Information

4.

It is recommended that the thermal shipping container not be opened for more than 3 minutes at a time and not more than twice a day. The thermal shipping container may be used


When you are ready to thaw or use the vaccine

• Discard vaccine vials in a sharps container as medical waste to ensure they are permanently destroyed. Discard vial trays as medical waste so they cannot

• Have been fully discharged and used to administer vaccinations

• Are more than 6 hours from time of dilution

• Have not been at room temperature for more than 2 hours

• Do not pool excess vaccine from multiple vials

• Each dose must contain 0.3 mL of vaccine

• Do not shake.

3.

After dilution, vials of Pfizer-BioNTech COVID-19 Vaccine contain six doses of 0.3 mL of vaccine. Low dead-volume syringes and/or needles can be used to extract six doses from a single vial. It is recommended that each dose be administered in a single injection. Care should be taken to prevent the introduction of extraneous material by

Before dilution, vials contain 16.8 mL of Sodium Chloride Injection, USP (0.9%) and Pfizer-BioNTech COVID-19 Vaccine. Do not add more than 0.1 mL of diluent. As such, this product is not recommended for use in children under 16 years of age. It is estimated that 1 mL of the 0.9% saline solution will be required to

Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and

New York, NY 10017

For additional resources, please refer to www.cvdvaccine-us.com for more information about storage and handling of dry ice

Unsolicited Animal Inspections cannot be used for more than 3 hours.

The vaccine should be administered to the deltoid muscle in adults and children

Aside from the diluent volume, the thermal storage container may be at room temperature for up to 24 hours following receipt or return to frozen storage for subsequent use. If the vaccine is to be administered within 2 hours prior to thawing or use, it should be kept in the thermal shipping container. If the vaccine is to be stored in a refrigerator or freezer for any extended period of time, it should be kept in the thermal shipping container at a temperature not exceeding -112°F (-76°C) or -112°F (-76°C) or -112°F (-76°C).

The thermal shipping container is designed to maintain the contents at the appropriate temperature for 24 hours. After 24 hours, the thermal shipping container should be removed from the cold chain and the contents transferred to a refrigerated or freezer environment as appropriate.

Dry Ice can be hazardous. Take necessary precautions by reviewing the Dry Ice Safety Data Sheet and consult with your Occupational Health Department. Ensure there is proper ventilation and always proper safety glasses with side shields or safety goggles and waterproof insulated gloves when handling dry ice.

As many as 2,200 doses can be shipped in a thermal shipping container and must be kept at temperatures between 2°C to 8°C (36°F to 46°F) to prevent exposure to temperatures above or below this range.

Use within 6 hours from time of shipment. If not used within 6 hours, it should be discarded.

Pfizer-BioNTech COVID-19 Vaccine Storage and Handling Reference Guide and Video at www.cvdvaccine.com for more information about

Available at www.cvdvaccine-us.com

Refer to the re-icing guidelines in the Pfizer-BioNTech COVID-19 Vaccine Storage and Handling Reference Guide and Video at www.cvdvaccine.com for more information about

• Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent

• Use appropriate treatment used to manage immediate reactions react more immediately if available. In the event of an anaphylactic reaction, the physician or

• Do not use if liquid is discolored or if other particles are observed

• It is estimated that 1 mL of the 0.9% saline solution will be required to

• The vaccine should be administered to the deltoid muscle in adults and children

• Do not freeze thawed vials.

• Do not pool excess vaccine from multiple vials

• Each dose must contain 0.3 mL of vaccine

• Do not shake.

3.

After dilution, vials of Pfizer-BioNTech COVID-19 Vaccine contain six doses of 0.3 mL of vaccine. Low dead-volume syringes and/or needles can be used to extract six doses from a single vial. It is recommended that each dose be administered in a single injection. Care should be taken to prevent the introduction of extraneous material by

Before dilution, vials contain 16.8 mL of Sodium Chloride Injection, USP (0.9%) and Pfizer-BioNTech COVID-19 Vaccine. Do not add more than 0.1 mL of diluent. As such, this product is not recommended for use in children under 16 years of age. It is estimated that 1 mL of the 0.9% saline solution will be required to

Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and

New York, NY 10017

For additional resources, please refer to www.cvdvaccine-us.com for more information about storage and handling of dry ice

Unsolicited Animal Inspections cannot be used for more than 3 hours.

The vaccine should be administered to the deltoid muscle in adults and children

Aside from the diluent volume, the thermal storage container may be at room temperature for up to 24 hours following receipt or return to frozen storage for subsequent use. If the vaccine is to be administered within 2 hours prior to thawing or use, it should be kept in the thermal shipping container. If the vaccine is to be stored in a refrigerator or freezer for any extended period of time, it should be kept in the thermal shipping container at a temperature not exceeding -112°F (-76°C) or -112°F (-76°C) or -112°F (-76°C).

Dry Ice can be hazardous. Take necessary precautions by reviewing the Dry Ice Safety Data Sheet and consult with your Occupational Health Department. Ensure there is proper ventilation and always proper safety glasses with side shields or safety goggles and waterproof insulated gloves when handling dry ice.

As many as 2,200 doses can be shipped in a thermal shipping container and must be kept at temperatures between 2°C to 8°C (36°F to 46°F) to prevent exposure to temperatures above or below this range.

Use within 6 hours from time of shipment. If not used within 6 hours, it should be discarded.

Pfizer-BioNTech COVID-19 Vaccine Storage and Handling Reference Guide and Video at www.cvdvaccine.com for more information about

Available at www.cvdvaccine-us.com

Refer to the re-icing guidelines in the Pfizer-BioNTech COVID-19 Vaccine Storage and Handling Reference Guide and Video at www.cvdvaccine.com for more information about

• Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent

• Use appropriate treatment used to manage immediate reactions react more immediately if available. In the event of an anaphylactic reaction, the physician or

• Do not use if liquid is discolored or if other particles are observed

• It is estimated that 1 mL of the 0.9% saline solution will be required to

• The vaccine should be administered to the deltoid muscle in adults and children

• Do not freeze thawed vials.

3.

After dilution, vials of Pfizer-BioNTech COVID-19 Vaccine contain six doses of 0.3 mL of vaccine. Low dead-volume syringes and/or needles can be used to extract six doses from a single vial. It is recommended that each dose be administered in a single injection. Care should be taken to prevent the introduction of extraneous material by

Before dilution, vials contain 16.8 mL of Sodium Chloride Injection, USP (0.9%) and Pfizer-BioNTech COVID-19 Vaccine. Do not add more than 0.1 mL of diluent. As such, this product is not recommended for use in children under 16 years of age. It is estimated that 1 mL of the 0.9% saline solution will be required to

Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and